Wed, Dec 17, 2014, 9:33 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Green Dot Corporation Message Board

janebang83 1208 posts  |  Last Activity: 9 hours ago Member since: May 28, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    chrisse angry! chrisse type with hammer! arrggh!

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    We feel your pain...

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    No, she will likely be institutionalized by the time Relday hits the market, if it hits the market...

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    Haha! chrisse and madcow, relday patients # 1 and 2...

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    Haha!

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    My concern is that Roger has failed to adequately understand the market, yet again. He's still executing a 4-year-old plan, failing to reconcile the realities that have since occurred in the market (not unlike some of the more naive "investors" on this mb...)

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    Look at posts contrasting Risperdal Consta and Invega Sustenna - I think that answers my question - independently verified as no real advantage (risperidone).

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    Above two posts are quotes/excerpts found on the topic...

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    The journal study is unlikely to hurt J&J sales, said Glenn Novarro, a New York-based analyst at RBC Capital Markets, in an interview. The company has already shifting sales to a newer antipsychotic injection, the once-a-month Invega Sustenna, he said.

    Risperdal Consta “is yesterday’s drug,” Novarro said. “It’ll have zero impact on the stock,” he said of the study.

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    Johnson & Johnson (JNJ)’s antipsychotic medicine Risperdal Consta, its third-best-selling drug, fared no better than less expensive treatments at keeping schizophrenia patients out of the hospital, U.S. researchers said.

    Patients on Risperdal Consta, a twice-monthly injection, ended up in the hospital 39 percent of the time during the three-year analysis, about the same as those who took other drugs as a daily pill, a study released yesterday in the New England Journal of Medicine said. People on the J&J treatment also reported more headaches and muscle tremors among their side effects, scientists found.

    Risperdal Consta generated $1.5 billion in sales last year for New Brunswick, New Jersey-based J&J. Today’s findings undercut what has been the injection’s main selling point: that patients are more likely to stay on the medicine because it’s taken less often, said Robert Rosenheck, the study’s lead author. Researchers saw no better adherence after the initial two-week dose, he said.

    “This study gives no reason why the use of this treatment should be increased” over other drugs, said Rosenheck, a researcher with the U.S. Department of Veterans Affairs, which funded the study. “It may be effective for individual patients, but as a matter of policy, this is an expensive treatment and there’s no reason to aggressively promote it.”

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    One thing I don't know if anyone knows: why did J&J stop development of monthly injection for Relday with ALKS back in 2009? ("[J&J is] switching injections from a dependency on risperdone to Invega Sustenna" cf. Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand

    Worldwide sales of Risperdal Consta for ALKS) came in at $348 million in its first quarter.

  • Reply to

    Future Share Holder?

    by dewless13 11 hours ago
    janebang83 janebang83 9 hours ago Flag

    Hey! I resent that! :^)

  • Reply to

    Future Share Holder?

    by dewless13 11 hours ago
    janebang83 janebang83 9 hours ago Flag

    Not currently - you're ALWAYS the most hated because you are insipid, fake, and insufferable...

  • Reply to

    Relday

    by janebang83 9 hours ago
    janebang83 janebang83 9 hours ago Flag

    In other words, based on management performance over the past year, my concern is Relday is another debacle where management will be found "surprised" at the "negativity" surrounding its use, will be "surprised" at difficulty in getting adequate population of children for phase trials, and will be "surprised" to see that, if it stumbles into approval, it's TRx ramp will be slow (like ZGNX). I have NO CONFIDENCE in Roger and team to do any better on this pipeline...

  • janebang83 by janebang83 9 hours ago Flag

    I have had a concern for a long time and may as well post it. I doubt Relday is going to be a block buster. I think it's another that, while different than other formulations, the "market" (i.e., prescribers) isn't really going to appreciate its differentiation materially. So comments that Relday is going to kick this pps to $10, am not buying it at all...

    In this end, it's just another hack job by Roger to attempt to leverage someone else's invention (DURECT's in this case).

    OK, that last part was admittedly a slam, but...

    1. The major players in the antipsychotics market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline. Eli Lilly's Zyprexa has the largest market share of the market, at 26% ($4.70 billion), while AstraZeneca's Seroquel, at 2nd place ($4.45 billion) remains the most widely prescribed antipsychotic.

    2. 29% of the antipsychotic market is for "long-term care" (the balance being retail + mail-order)

    3. On top of 11/2013 J&J's $2.2B settlement for Risperdal (it's brand name for the generic risperidone (3rd largest settlement in pharma history) that it "improperly promoted the antipsychotic drug Risperdal to older adults, children and people with developmental disabilities"

    4. The intramuscular preparation, marketed as Risperdal Consta, can be given once every two weeks. It is slowly released from the injection site. This method of administration may be used on sanctioned patients (detained), who are refusing, or consenting patients who may have disorganized thinking and cannot remember to take their daily doses - not exactly an industry segment that is going to warrant high costs (IMO)
    5. 232 variants of risperidone available globally (WHO document)
    6. Use in children may be problematic: Children and elderly may need to have oral twice daily dosing during initiation and titration of risperidone and then can switch to oral once daily when maintenance dose is reached. Risperidone_24_A_Ad_Final.pdf

  • Reply to

    Emotions flying high

    by licky_mywalker Dec 11, 2014 6:46 PM
    janebang83 janebang83 Dec 11, 2014 7:06 PM Flag

    She keeps sticking her face right back in the woodchipper, zombie that she is...

  • Reply to

    About madcow's privacy

    by stockcow_is_a_mons_louse Dec 11, 2014 4:18 PM
    janebang83 janebang83 Dec 11, 2014 7:05 PM Flag

    You LIAR...

  • Reply to

    About madcow's privacy

    by stockcow_is_a_mons_louse Dec 11, 2014 4:18 PM
    janebang83 janebang83 Dec 11, 2014 7:03 PM Flag

    Quotes, madcow! THose are Quotes, not "twisting your posts" - jlt19067 correctly surmises - there is NOTHING innocent about you. You merit every comment, you illiterate waste product..

  • Reply to

    About madcow's privacy

    by stockcow_is_a_mons_louse Dec 11, 2014 4:18 PM
    janebang83 janebang83 Dec 11, 2014 4:24 PM Flag

    Wait for it - she'll go ALL CAPS MODE on you and accuse you of stalking. Apparently in her parochial education, "quoting" means the same as "stalking" Whatev...

  • Reply to

    Mr. Hawley

    by stockgal25 Dec 11, 2014 2:34 PM
    janebang83 janebang83 Dec 11, 2014 2:50 PM Flag

    You have a direct line to Hawley - then why post here? Why not tell him directly - and bring us his reply...

GDOT
21.65+0.22(+1.03%)Dec 17 4:04 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
R.R. Donnelley & Sons Company
NasdaqGSWed, Dec 17, 2014 4:00 PM EST
Kellogg Company
NYSEWed, Dec 17, 2014 4:02 PM EST